TransMedics Group (TMDX) FDA Approvals $94.19 -2.24 (-2.33%) As of 03:23 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest TransMedics Group's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by TransMedics Group (TMDX). Over the past two years, TransMedics Group has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as OCS™. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. OCS™ Heart System FDA Regulatory Events OCS™ Heart System is a drug developed by TransMedics Group for the following indication: For patients with end-stage lung, heart, and liver failure. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. FDA Approval - February 9,2026Fda Approval Investigational Device ExemptionDrug: OCS™ Heart SystemAnnounced Date: February 9, 2026Indication: For patients with end-stage lung, heart, and liver failureAnnouncementTransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial.AI SummaryTransMedics Group, Inc. announced that the U.S. Food and Drug Administration has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial. This IDE approval clears a key regulatory step and allows TransMedics to conduct a controlled clinical study in the United States using its next-generation Organ Care System (OCS) for heart transplants. The company can now enroll patients, collect safety and effectiveness data, and operate under the FDA-approved trial protocol. The trial will evaluate the updated OCS technology designed to keep donor hearts functioning outside the body for longer and under better conditions than cold storage. If successful, the study could support future regulatory filings and broader clinical use of the device, potentially increasing donor heart availability and improving transplant outcomes. TransMedics will now move forward with site activation and patient enrollment as outlined in the trial plan.Read AnnouncementConditional approval - August 4,2025Conditional Approval Investigational Device ExemptionDrug: OCS™ Heart SystemAnnounced Date: August 4, 2025Indication: For patients with end-stage lung, heart, and liver failureAnnouncementTransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), allowing the company to proceed with the initiation of its Next-Generation OCS ENHANCE Heart trial.AI SummaryTransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), clearing the way for the company’s Next-Generation OCS ENHANCE Heart trial. This two-part study will use the Organ Care System (OCS) Heart platform to test prolonged heart perfusion in Part A and compare OCS perfusion to standard cold storage in donation after brain death (DBD) cases in Part B. With over 650 patients planned, it is expected to become the largest heart preservation trial worldwide. Part B will include DBD hearts not currently eligible for OCS perfusion, with the goal of expanding future clinical indications. TransMedics plans to start enrolling patients in the fourth quarter of 2025, and full trial details will be posted on clinicaltrials.gov. Company leaders view the ENHANCE Heart trial as a key step toward broader clinical adoption in 2026 and beyond, aiming to improve organ quality, increase transplant success, and reset the standard of care for heart transplantation.Read Announcement TransMedics Group FDA Events - Frequently Asked Questions Has TransMedics Group received FDA approval? As of now, TransMedics Group (TMDX) has not received any FDA approvals for its therapy in the last two years. What drugs has TransMedics Group submitted to the FDA? In the past two years, TransMedics Group (TMDX) has reported FDA regulatory activity for OCS™ Heart System. What is the most recent FDA event for TransMedics Group? The most recent FDA-related event for TransMedics Group occurred on February 9, 2026, involving OCS™ Heart System. The update was categorized as "FDA Approval," with the company reporting: "TransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial." What conditions do TransMedics Group's current drugs treat? Currently, TransMedics Group has one therapy (OCS™ Heart System) targeting the following condition: For patients with end-stage lung, heart, and liver failure. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagene FDA EventsAlnylam Pharmaceuticals FDA EventsGE HealthCare Technologies FDA EventsGenprex FDA EventsHUTCHMED FDA EventsOpus Genetics FDA EventsLigand Pharmaceuticals FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsRegeneron Pharmaceuticals FDA EventsTvardi Therapeutics FDA EventsBiohaven FDA EventsJohnson & Johnson FDA EventsActuate Therapeutics FDA EventsEnlivex Therapeutics FDA EventsImmuneering FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Insulet FDA Events Teleflex FDA Events Haemonetics FDA Events MiniMed Group FDA Events Pulse Biosciences FDA Events AxoGen FDA Events Establishment Labs FDA Events NovoCure FDA Events PROCEPT BioRobotics FDA Events Alpha Tau Medical FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:TMDX last updated on 2/9/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Approval - February 9,2026Fda Approval Investigational Device ExemptionDrug: OCS™ Heart SystemAnnounced Date: February 9, 2026Indication: For patients with end-stage lung, heart, and liver failureAnnouncementTransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial.AI SummaryTransMedics Group, Inc. announced that the U.S. Food and Drug Administration has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial. This IDE approval clears a key regulatory step and allows TransMedics to conduct a controlled clinical study in the United States using its next-generation Organ Care System (OCS) for heart transplants. The company can now enroll patients, collect safety and effectiveness data, and operate under the FDA-approved trial protocol. The trial will evaluate the updated OCS technology designed to keep donor hearts functioning outside the body for longer and under better conditions than cold storage. If successful, the study could support future regulatory filings and broader clinical use of the device, potentially increasing donor heart availability and improving transplant outcomes. TransMedics will now move forward with site activation and patient enrollment as outlined in the trial plan.Read Announcement
Conditional approval - August 4,2025Conditional Approval Investigational Device ExemptionDrug: OCS™ Heart SystemAnnounced Date: August 4, 2025Indication: For patients with end-stage lung, heart, and liver failureAnnouncementTransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), allowing the company to proceed with the initiation of its Next-Generation OCS ENHANCE Heart trial.AI SummaryTransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), clearing the way for the company’s Next-Generation OCS ENHANCE Heart trial. This two-part study will use the Organ Care System (OCS) Heart platform to test prolonged heart perfusion in Part A and compare OCS perfusion to standard cold storage in donation after brain death (DBD) cases in Part B. With over 650 patients planned, it is expected to become the largest heart preservation trial worldwide. Part B will include DBD hearts not currently eligible for OCS perfusion, with the goal of expanding future clinical indications. TransMedics plans to start enrolling patients in the fourth quarter of 2025, and full trial details will be posted on clinicaltrials.gov. Company leaders view the ENHANCE Heart trial as a key step toward broader clinical adoption in 2026 and beyond, aiming to improve organ quality, increase transplant success, and reset the standard of care for heart transplantation.Read Announcement